Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -60.30% | 172.58% | 277.66% | 536.93% | 394.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.52% | 44.59% | -82.87% | -62.97% | -35.17% |
| Operating Income | -80.52% | -44.59% | 82.87% | 62.97% | 35.17% |
| Income Before Tax | -80.52% | -44.59% | 82.87% | 62.97% | 35.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.52% | -44.65% | 82.87% | 62.97% | 35.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.52% | -44.65% | 82.87% | 62.97% | 35.17% |
| EBIT | -80.52% | -44.59% | 82.87% | 62.97% | 35.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 94.75% | 97.65% | 99.84% | 99.82% | 94.82% |
| Normalized Basic EPS | 94.75% | 97.65% | 99.84% | 99.82% | 94.82% |
| EPS Diluted | 94.75% | 97.65% | 99.84% | 99.82% | 94.82% |
| Normalized Diluted EPS | 94.75% | 97.65% | 99.84% | 99.82% | 94.82% |
| Average Basic Shares Outstanding | 3,339.58% | 6,053.18% | 10,430.45% | 20,753.79% | 1,153.21% |
| Average Diluted Shares Outstanding | 3,339.58% | 6,053.18% | 10,430.45% | 20,753.79% | 1,153.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |